Taysha Gene Therapies (TSHA) Operating Leases (2022 - 2025)
Historic Operating Leases for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $16.5 million.
- Taysha Gene Therapies' Operating Leases fell 701.37% to $16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year decrease of 701.37%. This contributed to the annual value of $17.4 million for FY2024, which is 839.97% down from last year.
- Latest data reveals that Taysha Gene Therapies reported Operating Leases of $16.5 million as of Q3 2025, which was down 701.37% from $16.8 million recorded in Q2 2025.
- In the past 5 years, Taysha Gene Therapies' Operating Leases ranged from a high of $20.4 million in Q4 2022 and a low of $16.5 million during Q3 2025
- For the 4-year period, Taysha Gene Therapies' Operating Leases averaged around $18.3 million, with its median value being $18.3 million (2024).
- Per our database at Business Quant, Taysha Gene Therapies' Operating Leases plummeted by 839.97% in 2024 and then plummeted by 701.37% in 2025.
- Taysha Gene Therapies' Operating Leases (Quarter) stood at $20.4 million in 2022, then decreased by 7.27% to $19.0 million in 2023, then fell by 8.4% to $17.4 million in 2024, then dropped by 4.92% to $16.5 million in 2025.
- Its Operating Leases was $16.5 million in Q3 2025, compared to $16.8 million in Q2 2025 and $17.1 million in Q1 2025.